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A comparison of the initial orthotic
effects of functional electrical stimulation
and ankle-foot orthoses on the speed and
oxygen cost of gait in multiple sclerosis
Linda (Miller) Renfrew1,2, Anna C Lord1, Angus K McFadyen3, Danny Rafferty2,
Rebecca Hunter1, Roy Bowers4, Paul Mattison1, Owen Moseley5 and Lorna Paul2
Abstract
Background: Foot drop affects walking in people with multiple sclerosis (pwMS). This study compares the initial
orthotic effects of two treatments for foot drop: ankle-foot orthoses (AFO) and functional electrical stimulation
(FES), on the speed and oxygen cost of walking in MS.
Method and materials: Seventy-eight pwMS were randomised to receive AFO or FES (ODFS PACE (OML, Salisbury,
UK)). Participants completed the 25-ft walk test (25ftWT) and 5-min self-selected walk test (5minSSWT), from which
oxygen cost was determined, with and without their device. Between-, within- and sub-group analyses (based on baseline
walking speed of <0.8m/s (slow) or 0.8m/s (fast)) were undertaken.
Results: No significant differences between baseline measures were observed. The AFO group walked significantly
slower than the FES group (5minSSWT, p¼ 0.037, 0.11m/s). The AFO group walked significantly slower with than
without AFO (25ftWT, p¼ 0.037), particularly in the fast-walking group ( p¼ 0.011). The slow-walking FES group walked
significantly faster with FES than without (25ftWT; p¼ 0.029, 5minSSWT; p¼ 0.037). There were no differences in the
fast-walking FES group or in the oxygen cost for either device.
Conclusion: AFO reduced walking speed, particularly in fast walkers. FES increased walking speed in slow, but not fast
walkers.
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Introduction
Multiple sclerosis (MS) is the most common neuro-
logical condition resulting in physical disability of the
working age population in the UK.1 Mobility deterior-
ates over time in people with MS (pwMS), and changes
in gait are the most observable contributor to disability,
with only around 50% of pwMS remaining ambulatory
without assistance 15 years from disease onset.2,3 Foot
drop is a commonly observed gait problem in pwMS. It
presents as reduced dorsiﬂexion at heel strike and toe
clearance during the swing phase of walking.4 The con-
sequences of foot drop for pwMS may include: reduced
walking speed, higher levels of fatigue and an increased
eﬀort of walking in comparison to healthy controls.3–6
Foot drop may also impact on work and leisure activ-
ities and contributes to a reduced quality of life in
pwMS.7–9
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Conventionally, foot drop has been treated using
ankle-foot orthoses (AFO). AFO, worn on the lower
leg and foot, are designed primarily to prevent excessive
ankle plantarﬂexion where there is a loss of, or weak,
dorsiﬂexion and eversion, by supporting the foot in a
neutral position. An alternative treatment for foot
drop, functional electrical stimulation (FES) was ﬁrst
developed by Liberson et al.10 and is usually delivered
via skin surface electrodes which stimulate the common
peroneal nerve.10 The resulting contraction of anterior
tibialis during the swing phase of gait, which is trig-
gered by either a foot switch or tilt mechanism, aug-
ments ankle dorsiﬂexion and assists foot drop
impairment.
The eﬀects of FES and AFO on walking speed, a
commonly evaluated outcome in both AFO and FES
studies, are described in terms of orthotic and thera-
peutic eﬀects. A therapeutic eﬀect is described as the
change in a relevant variable (e.g. walking speed) mea-
sured over time without the device on. An orthotic
eﬀect is the change in the variable with the device com-
pared to without, which is observed at any given time.
The change seen on the ﬁrst day of its use is described
as the initial orthotic eﬀect and is the most commonly
reported eﬀect in FES literature.11 Although neither
device are intended to be used on a one oﬀ basis, and
initial eﬀects are likely to be compensatory in nature, it
is still important to cognisant of these initial orthotic
eﬀects. This will allow clinicians to understand how
these devices aﬀect walking initially in pwMS, which
may impact on patient compliance over the longer
term.
There have been only four small studies to date
investigating the impact of AFOs in pwMS, which
report mixed eﬀects on walking speed and balance.12–15
A recent systematic review and meta-analysis found
clinically meaningful orthotic eﬀects of FES on gait
speed in pwMS; however, analysis was primarily
based on non-randomised trials of low methodological
quality.11 Previous FES studies have also evaluated the
impact of FES on the oxygen cost of walking,16–21
which is a valid physiological marker of locomotor
impairment in pwMS.22 There is only one case series
study (n¼ 4) which has compared the ongoing orthotic
eﬀect of AFOs and FES for foot drop in MS and
reports variable eﬀects.14
A gait speed of 0.8m/s has been identiﬁed as the
speed at which pwMS need to walk in order to achieve
successful community ambulation.5 Miller et al. previ-
ously noted a diﬀerential eﬀect of FES which was
dependant on self-selected walking speed. With FES,
improvements were noted in pwMS who walked at
walking speeds of< 0.8m/s, but not> 0.8m/s.20
Further investigation of the potential impact of self-
selected walking speed on the eﬀect of FES and AFO
is required and will help inform the clinical prescription
of such devices.
The aim of this study was to compare the initial
orthotic eﬀect of AFO and FES on the speed (in both
short and long walking tests) and oxygen cost of walk-
ing in pwMS with persistent foot drop and investigate
the impact of walking speed on the eﬀect of these
devices.
Methods
A randomised trial was conducted to compare the
eﬀects of AFO and FES in pwMS. This paper presents
the initial orthotic eﬀects of the two devices on the
speed and energy cost of gait. Neither the assessor
nor the participants were blind to the group allocation.
Participants
The sample size for this study was estimated based on
the data from the 5-min self-selected walk test
(5minSSWT) previously collected in FES studies by
our group.6,19,20 At a power of 90% and a 5% level
of signiﬁcance a minimum of 37 participants in each
group would be required in order to detect a change
of at least 75% of 1 standard deviation value (0.16 m/s).
Allowing for an estimated 15% attrition rate, a total of
84 participants were recruited.
Ethical approval for the study was granted by the
West of Scotland Research Ethics Committee and NHS
Ayrshire, and Arran Research and Development
department sponsored the study. Convenience sam-
pling was used to recruit 84 participants across seven
NHS health board sites in Scotland (Ayrshire and
Arran, Dumfries and Galloway, Greater Glasgow and
Clyde, Fife, Lanarkshire, Lothian and Tayside). MS
clinicians identiﬁed potential participants via their cur-
rent caseloads and invited them to attend for screening.
Participants who met the inclusion and exclusion cri-
teria and gave informed written consent were enrolled
in the study. Participants were included if they had: a
clinical diagnosis of MS which was stable (no change in
disability over previous three months), persistent foot
drop which was observable during a 5-min walk test
and no changes in medication or rehabilitation over
the previous three months. Participants were excluded
if they had: previously used AFO or FES for foot drop,
another neurological condition which could present
with foot drop, another condition signiﬁcantly impact-
ing on gait, moderate to severe cognitive impairment
(scored< 26 Montreal Cognitive Assessment test),
marked proximal weakness, moderate to marked
instability (foot or knee) in stance, other signiﬁcant
MS impairments impacting on gait or contraindications
to using FES.
2 Journal of Rehabilitation and Assistive Technologies Engineering
Enrolled participants were randomly allocated (1:1)
to receive either FES or AFO. A computer-generated
randomization scheme was created by the study statis-
tician (AKM), and the group allocation was placed in
consecutive numbered sealed opaque envelopes and
issued to participants by the research physiotherapists
(AL, RH) following consent.
Procedures
Demographics relating to age, gender, MS type, time
since diagnosis and disability were collected at the
screening visit. A neurological examination and assess-
ment of the Expanded Disability Status Scale (EDSS)
was undertaken by an unblinded assessor trained in the
Neurostatus Scoring System https://neurostatus.net/
index.php.23
Participants in the AFO group were assessed, and
ﬁtted two weeks later by an orthotist, with a custom-
made solid AFO according to the recommendations
made by the Best Practice Statement for AFO following
stroke,24 as there are no current speciﬁc recommenda-
tions for MS. All AFOs were made using 4.5mm poly-
propylene with trim lines anterior to the malleoli.
Reinforcements were added to the ankle section to
increase stiﬀness if required. The angle of the AFO
was inclined forward so that the tibia sat approximately
10 to the vertical to optimise kinetics and kinematics at
the knee and hip. The AFOs were individually ‘tuned’
by the addition or removal of small heel wedges, in
order to optimise gait for each individual participant.
Tuning AFOs has been found to positively impact on
knee hyperextension in stroke.25 Participants in the
FES group were set up and ﬁtted by a physiotherapist
trained and experienced in FES use. The Odstock
Dropped Foot Stimulator (ODFS) PACE (OML,
Salisbury) device was used. All units had a wired heel
switch and applied a 40Hz stimulation frequency.
Electrode position, pulse width and ramping param-
eters were adjusted to suit each participant by a
research assistant, a physiotherapist trained in FES
(AL). The intensity of the current amplitude ranged
from 17 to 72 mA which was determined at the FES
ﬁtting appointment/assessment visit as the ampli-
tude was both comfortable for the patient and achieved
adequate clearance of the foot during the swing phase
of gait.
Assessments were undertaken by the same research
assistant (RH). The primary outcome measure for
this study was the 5minSSWT. All participants
walked with and without their respective devices for
each walk test (described below). The order of testing
was randomised between participants. All odd num-
bered participants in each group undertook the walk-
ing tests with their device ﬁrst, and all even
numbered participants walked without their
device ﬁrst.
5-min self-selected walk test. Participants walked for 5min
on a level ﬂoor at their self-selected walking speed
around a 9.5m elliptical course, resulting in a 10 -m
shuttle length. The total distance walked was recorded
to allow a calculation of mean walking speed (m/s) over
the 5min. Participants walked on two occasions, with
and without their device and rested for 20min between
each test. This protocol has been used previously in
FES research by our group.6,19,20
Oxygen cost of walking. The COSMED K4b2 (Cosmed,
Rome, Italy) gas analysis system, facemask (Hans
Rudolph Inc., Kansas City, MO, USA) and Polar
heart-rate monitor (Polar, Finland) were ﬁtted to par-
ticipants. The COSMED system was calibrated prior to
assessment according to the manufacturer’s instruc-
tions. All participants rested in a seated position for
5min prior to the test in order to estimate resting
metabolism. Oxygen uptake per kilogram body weight
(mLmin1kg1) was recorded and the oxygen cost per
unit distance walked (mLmin1kg1m1) was calcu-
lated using data between min 3 and 4 of the
5minSSWT when a steady state was achieved. The
COSMED system has good test–retest reliability,26 is
a valid measure for oxygen uptake in healthy adults27
and has been found to correlate with disability, fatigue,
walking speed and cadence in pwMS.28
25 foot walk test. The 25ftWT has been validated in MS
as one of the three components of the Multiple
Sclerosis Functional Composite Score.29 The partici-
pant was instructed to walk along a clearly marked
25 ft course as quickly and as safely as possible. This
was repeated twice walking with and then without the
device. The mean time of the two walks was used to
calculate the gait speed in m/s. Motl et al. found the
25ftWT to be highly reliable, valid and responsive
measure which captures clinically meaningful change
in walking in MS.30
Data analysis
Descriptive statistics for demographic data are pre-
sented as means and standard deviations unless other-
wise indicated. Where data were normally distributed,
paired t-tests were used to explore initial orthotic eﬀects
for each of the devices with respect to the 5minSSWT,
25ftWT and oxygen cost of walking. Two sample t-tests
were used to explore between-group comparisons.
Participants in each group were also split into two
groups by applying the variable of baseline gait speed
(5minSSWT without device), using 0.8m/s as cut-oﬀ
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point, which deﬁnes walking speed required for com-
munity ambulation in pwMS.5 Analysis for the sub-
groups was undertaken as for complete groups.
Signiﬁcance was assumed when p< 0.05, and all ana-
lyses were performed on SPSS v24.
Results
A total of 192 pwMS were issued with the patient infor-
mation sheet, and 97 attended for screening. Eighty-
four participants met the criteria for inclusion following
screening and consented to participate in the study
between September 2014 and January 2017 (Figure 1).
Six participants withdrew from the study between the
screening and assessment visit, ﬁve from the AFO
group and one from the FES, leaving 78 participants
completing the assessment.
There were no signiﬁcant diﬀerences between the
groups except for gender, where there was a signiﬁ-
cantly greater percentage of males (n¼ 19 (51.6%)) in
the AFO group in comparison to the FES group (n¼ 9
(22%)) ( p¼ 0.014) (Table 1).
Between-group differences
There were no signiﬁcant between-group diﬀerences for
any of the baseline measures which included the speed
(5minSSWT and 25ftWT) and oxygen cost of walking
without the device. There were no signiﬁcant diﬀerences
for the 25ftWT or oxygen cost of walking with the
device. There were, however, between-group diﬀerences
walking with the device for the 5minSSWT, with the
AFO group walking signiﬁcantly slower ( p¼ 0.043)
than the FES group (Table 2). There were no
between-group diﬀerences found with or without the
AFO or FES for any of the walking tests in the slow
(<0.8m/s) or fast (>0.8m/s) walking sub-groups.
Within-group differences
Participants in the AFO group walked slower with the
AFO than without, which was signiﬁcant for the
25ftWT ( p¼ 0.037) but not the 5minSSWT (Table 3).
There were no signiﬁcant diﬀerences walking with FES
for any of the outcome measures, although there was a
small non-signiﬁcant increase in walking speed
observed for the 25ftWT (Table 3).
Sub-group analysis
Participants in the slow walking group walked signiﬁ-
cantly faster with FES in comparison to without for
both the 25ftWT ( p¼ 0.029) and 5minSSWT
( p¼ 0.037). This eﬀect, however was not seen with
AFOs. Participants in the fast walking group, walked
signiﬁcantly slower with an AFO than without for the
Assessed for eligibility (n= 96)  
Excluded  (n=12) 
♦ Not meeting inclusion criteria (n=11) 
♦ Declined to participate (n= 1)
Analysed  (n=37) 
♦ Excluded from analysis (n=0)
Allocated to AFO  (n= 42) 
♦ Received allocated intervention (n=37)
♦ Did not receive allocated intervention 
• Not happy with randomisaon (n=4) 
• No longer able to commit (n=1) 
Allocated to FES (n=42) 
♦ Received allocated intervention (n=41)
♦ Did not receive allocated intervention 
• Family commitments (n=1)
Analysed  (n=41) 
♦ Excluded from analysis (n=0)
Allocation 
Analysis 
Randomized (n= 84) 
Enrollment 
Figure 1. Consort diagram.
AFO: ankle foot orthoses; FES: functional electrical stimulation.
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25ftWT ( p¼ 0.011). There were no diﬀerences observed
in any of the other walking outcomes when walking
with either AFOs or FES in the fast-walking group.
There were no diﬀerences in oxygen cost in any of the
sub-groups (Table 4).
Discussion
This randomised trial is the ﬁrst to compare the initial
orthotic eﬀects of AFO and FES for the treatment of
foot drop in pwMS. AFO reduced walking speed in the
short walking test, and this was most noticeable in fast
walkers, whose baseline walking speeds were> 0.8m/s.
Clinician-setup FES increased walking speed in slow
walkers, who walked at speeds of <0.8m/s. There was
no diﬀerence in the oxygen cost of walking with either
device. The results from this study may indicate that
pwMS who walk at speeds of <0.08m/s gain positive
initial orthotic eﬀects from FES, but not AFOs, thus
giving clinicians some insight into how these devices
aﬀect walking following an initial set up. These results
may help inform clinical decision making and patient
understanding, thus going some way to support patient
compliance of these devices. Further investigation,
however, is required to understand the possible mech-
anisms involved.
There has only been one study, a case series (n¼ 4),
which has compared AFO with FES in pwMS.14
Sheﬄer et al.14 noted variable eﬀects of both devices
and found that the participant with the fastest baseline
walking speed (1.01m/s) walked signiﬁcantly slower
with AFO but not with FES. These results concur
with those observed in the current study. Only four
studies to date have investigated the eﬀect of AFOs
on the speed of walking in MS and all have small
sample sizes.12–15 Of these, only one study (n¼ 14)
investigated the initial orthotic eﬀect and found that
participants walked 14.3–72% slower in the 10 mWT
with an AFO.12 This eﬀect, although much smaller in
the current study (1.3 (slow walkers) – 8.1% (fast walk-
ers)), suggests that AFOs have a negative initial orth-
otic eﬀect in faster walkers over short distances. The
AFOs used in the current study were rigid and were
therefore perhaps more likely than the FES to have
an immediate impact on gait biomechanics, thus result-
ing in an initial reduction in walking speed. It is feasible
that pwMS will accommodate to AFO use over time.
Two previous non-randomised trials investigating the
ongoing orthotic eﬀect of AFOs on the 25ftWT13 in
MS and the 6minWT15 in stroke and MS did ﬁnd
small non-signiﬁcant increases in walking speed,
which supports this explanation. Further investigation
particularly examining the impact of AFO on the kin-
etic and kinematic aspects of gait is needed to under-
stand the possible mechanisms involved.
This study found no initial orthotic eﬀect with FES
for either short or long walking tests in MS. This is in
contrast with a recent systematic review and meta-ana-
lyses of FES, where 9 of the 15 studies reviewed
reported signiﬁcant initial orthotic eﬀects on combined
short walking tests.11 Meta-analyses revealed a signiﬁ-
cant initial orthotic eﬀect (t¼ 2.14, p¼ 0.016), with a
mean increase in walking speed of 0.05m/s (7.1%).11
This increase is larger than that observed in the current
study for the 25ftWT which was 0.03m/s (3.4%) over-
all, 0.05m/s (6.5%) for the slow walkers and no change
for the fast walkers. Diﬀerences in the mean baseline
Table 1. Mean, standard deviations and between-group differ-
ences for demographic data.
AFO FES p
n 37 41
Age (yrs) 0.657a
Mean 51.6 50.5
sd 11.3 10.2
Gender, 0.014b,c
%Male 19 (51.4) 9 (22.0)
Type of MS (%) 0.635b
Benign 0 1 (2.4)
PP 7 (18.9) 6 (14.6)
SP 10 (27.0) 8 (19.5)
RR 16 (43.2) 18 (43.9)
Unknown 4 (10.8) 8 (19.5)
Time since diagnosis [yrs] 0.249d
Mean 10.4 7.6
sd 10.4 8.5
6
EDSS 0.113d
Mean 5.3 4.8
sd 1.3 1.4
Height (m) 0.214d
Mean 1.7 1.7
sd 0.12 0.11
Weight (kg) 0.207d
Mean 84.6 78.7
sd 22.7 18.2
BMI 0.603d
Mean 29.5 28.6
sd 6.8 6.6
yrs: years; sd: standard deviation; PP: primary progressive; SP: secondary
progressive; RR: relapsing remitting; EDSS: Extended Disability Status
Score; m: meters; kg: kilograms; BMI: body mass index; MS: multiple
sclerosis; AFO: ankle foot orthoses; FES: functional electrical stimulation.
at-test.
bChi-square.
cStatistically significant.
dMann-Whitney.
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Table 4. Initial orthotic effect of AFO and FES for sub-groups of participants who walked< 0.8m/s and 0.8m/s (mean 5minSSWT
without FES).
Without device Mean (sd) With device Mean (sd) Mean difference (sd) p
AFO slow walking group< 0.8m/s (n¼ 28)
25ftWT 0.76 (0.27) 0.75 (0.26) 0.01 (0.08) 0.512
5minSSWT 0.56 (0.15) 0.55 (0.16) 0.01 (0.09) 0.322
Oxygen cost 0.37 (0.18) 0.35 (0.14) 0.02 (0.08) 0.524
AFO fast walking group 0.8m/s (n¼ 9)
25ftWT 1.23 (0.28) 1.13 (0.22) 0.10 (0.09) 0.011a
5minSSWT 0.94 (0.09) 0.89 (0.13) 0.05 (0.11) 0.238
Oxygen cost 0.23 (0.05) 0.22 (0.04) 0.01 (0.04) 0.792
FES slow walking group< 0.8m/s (n¼ 25)
25ftWT 0.77 (0.28) 0.82 (0.29) 0.05 (0.10) 0.029a
5minSSWT 0.57 (0.16) 0.62 (0.18) 0.05 (0.11) 0.037a
Oxygen cost 0.34 (0.15) 0.32 (0.13) 0.02 (0.05) 0.101
FES fast walking group 0.8m/s (n¼ 16)
25ftWT 1.21 (0.21) 1.21 (0.22) 0.00 (0.11) 0.874
5minSSWT 1.00 (0.17) 0.93 (0.25) 0.07 (0.25) 0.251
Oxygen cost 0.21 (0.05) 0.23 (0.11) 0.02 (0.12) 0.532
AFO: ankle foot orthoses; 25ftWT: 25 foot walk test; 5minSSWT: 5-min self-selected walk test; FES: functional electrical stimulation; sd: standard
deviation.
aStatistically significant.
Table 3. Initial orthotic effect for the AFO and FES groups presenting the mean, standard deviations and within-group differences for
the 25ftWT (m/s), 5minSSWT (m/s) and oxygen cost of walking (ml/min/kg/m) for all participants.
Outcome measure Without device Mean (sd) With device Mean (sd) Mean difference (sd) p
AFO (n¼ 37)
25ftWT 0.87 (0.34) 0.84 (0.30) 0.03 (0.09) 0.037a
5minSSWT 0.66 (0.21) 0.63 (0.21) 0.03 (0.09) 0.126
Oxygen cost 0.33 (0.16) 0.31 (0.13) 0.02 (0.07) 0.487
FES (n¼ 41)
25ftWT 0.94 (0.34) 0.97 (0.33) 0.03 (0.11) 0.108
5minSSWT 0.74 (0.27) 0.74 (0.26) 0 (0.18) 0.986
Oxygen cost 0.29 (0.14) 0.29 (0.13) 0 (0.09) 0.835
AFO: ankle foot orthoses; 25ftWT: 25 foot walk test; 5minSSWT: 5-min self-selected walk test; FES: functional electrical stimulation; sd: standard
deviation.
aStatistically significant.
Table 2. Between-group comparisons for the initial orthotic effect of AFO and FES on the 25ftWT (m/s), 5minSSWT (m/s) and the
oxygen cost of walking (ml/min/kg/m).
Outcome measure AFO Mean (sd) FES Mean (sd) Mean difference (se) p
25ftWT (without) 0.87 (0.34) 0.94 (0.34) 0.07 (0.08) 0.366
25ftWT (with) 0.84 (0.30) 0.97 (0.33) 0.13 (0.07) 0.074
5minSSWT (without) 0.66 (0.21) 0.74 (0.27) 0.08 (0.05) 0.114
5minSSWT (with) 0.63 (0.21) 0.74 (0.26) 0.11 (0.05) 0.043a
Oxygen cost (without) 0.33 (0.16) 0.29 (0.14) 0.05 (0.04) 0.205
Oxygen cost (with) 0.31 (0.13) 0.29 (0.13) 0.03 (0.03) 0.428
25ftWT: 25 foot walk test; 5minSSWT: 5-min self-selected walk test; AFO: ankle foot orthoses; FES: functional electrical stimulation; sd: standard
deviation; se: standard error.
aStatistically significant.
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walking speed may be one factor which could account
for the variances between the studies. Participants in
the current study walked faster (0.94 0.34m/s
(25ftWT)) in comparison to participants in the system-
atic review (0.69 0.03m/s (combined short walk
tests)).11 All but one of the studies reviewed by Miller
et al.,11 however, were from non-RCT sources which
may also have resulted in an overestimation of their
ﬁndings and account for the diﬀerences observed.
The results from the 5minSSWTwere similar to those
seen by Miller et al.,11 who reported a small non-signif-
icant increase in walking speed with FES (0.02m/s
(3.3%) on combined long walking tests. Although
there was no overall eﬀect noted in the current study,
a signiﬁcant increase in walking speed was observed
with FES in the slow walking group for the
5minSSWT (0.05m/s, 8.8%, p¼ 0.037). A previous
study by Miller et al.20 reported a signiﬁcant increase
( p¼ 0.005) in walking speed in the 5minSSWT in pwMS
walking at speeds of< 0.8m/s, but not> 0.8m/s with
FES. Participants in the slow walking sub-group in
the current study had a mean baseline walking speed
(0.77 0.28m/s (25ftWT)) which was closer to that
reported by Miller et al.11 The results from the current
study therefore concur with those found by Miller
et al.20 and may be an indication that FES has a positive
initial orthotic eﬀect on walking speed in both short and
long walking tests in pwMS who walk slower but not
faster than 0.08m/s; however, further investigation is
required. Due to the small numbers of studies which
have previously investigated the impact of AFO on
walking speed in pwMS, there are no systematic reviews
or meta-analyses available for similar comparisons.
Although this study reports statistically signiﬁcant
changes with FES, it is important to consider the clin-
ical signiﬁcance of the changes observed. Paltamaa
et al. reported the minimally clinically important diﬀer-
ence (MCID) for gait speed to be between 0.08 and
0.14m/s in pwMS.31 The only change observed within
this range in the current study was a reduction in walk-
ing speed of 0.1m/s, with AFO, in the fast walking
group of nine participants. These changes therefore
would need to be veriﬁed by larger sample sizes.
The current study found no signiﬁcant diﬀerences in
oxygen cost when walking with either device. This
result is perhaps expected given the very small changes
observed in walking speed. Bregmen et al.15 reported a
12.1% reduction in the oxygen cost of walking with
AFO and Paul et al.6 and Miller et al.19 reported a
5.6% and 12% ( p¼ 0.017) reduction, respectively,
with FES; however, these studies reported ongoing
not initial orthotic eﬀects.
This study has a number of limitations. There were
signiﬁcant gender diﬀerences between the groups, with
the AFO group recruiting a greater percentage of males
compared to females. Although any gender eﬀects are
unlikely, it is unknown whether it may impact on the
initial orthotic eﬀect of either device.
This study was a multi-centre study, recruiting from
seven sites and involved three diﬀerent orthotists. Every
attempt to standardise AFO prescription was made;
however, variations between sites were observed
which may have impacted the results. Further sub-
group analysis found no impact of orthotic prescription
on either the short or long walking tests. Condie et al.
suggest that the function of AFOs may vary depending
on its fabrication.32 It is imperative therefore that future
studies should provide a clear description of AFO pre-
scription and assure standardisation. AFO prescription
for this study followed evidence-based recommenda-
tions from the best practice statement for stroke,24 as
there are no guidelines for MS. It may be that the pre-
scription recommended for stroke is not appropriate for
pwMS, and this may have inﬂuenced the results.
Further investigation is required to determine the
most eﬃcient AFO prescription for pwMS.
The 6-min Walk Test is a highly reliable (ICC: 0.95–
0.99)33 and responsive longer walking test commonly
used in MS.31 The validity, however, of the
5minSSWT used in this study has not been previously
tested. Although walking distances undertaken were
similar, there are diﬀerences in the pace, length of
track and equipment used (the 5minSSWT was under-
taken wearing a COSMED gas analyser), which may
inﬂuence the results, and thus the validity and reliability
of the 5minSSWT cannot be assumed.
The results presented from the sub-group analysis
must be treated with caution as sample sizes were
small and uneven across sub-groups.
Finally, it must be acknowledged that as the results
presented in this study are impairment based and spe-
ciﬁc to pwMS, the results as they stand add little to the
evidence base with regard to enhancing our under-
standing of the mechanisms of action or indeed the
likely impact of the devices on aspects of activity, par-
ticipation and quality of life.
Conclusion
This study, the ﬁrst randomised trial comparing the
initial orthotic eﬀect of AFO and FES for foot drop
in pwMS, found that pwMS with foot drop, who were
issued with AFOs initially, walked slower over longer
distances in comparison to those issued with FES when
walking with their devices. In addition, pwMS walked
slower with AFOs in comparison to without over short
distances and this was particularly noticeable in those
who walked faster. When FES was issued, there were
no diﬀerences in walking speed, except in those who
walked slowly where there was an increase in walking
Miller et al. 7
speed walking with FES in both short and longer walk-
ing distances compared to without.
This study only describes the initial journey of these
two devices which are usually prescribed for a min-
imum of months and often used for many years.
These results, however allow clinicians to compare the
initial orthotic eﬀects of AFO and FES on walking
speed, which will help inform clinical decision making
and prescription. This will also support patient compli-
ance over the longer term.
Further investigation of the ongoing orthotic and
therapeutic eﬀects is needed to inform our under-
standing of how these devices impact on the speed
and energy cost of walking over time. Future
research should also focus on a range of activity,
participation and gait kinematic outcomes which
will provide valuable information and help under-
stand the possible mechanisms involved, allowing
clinicians and pwMS to make informed evidence-
based decisions.
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